This study is in progress, not accepting new patients

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

a study on Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at La Jolla, California
Dates
study started
estimated completion
Principal Investigator
by Kathryn A Gold, MD

Description

Summary

The purpose of the study is to find out if the study drugs Avelumab, Cetuximab, and Palbociclib will slow or stop your cancer from getting worse, and whether it causes side effects. The second purpose is to measure whether your cancer responds to the study drugs Avelumab, Cetuximab, and Palbociclib. The study drugs Avelumab, Cetuximab, and Palbociclib are types of drugs called a monoclonal antibody. Monoclonal antibodies are made to recognize, target, and bind to specific proteins on cells the building blocks making up your tissues.

Official Title

A Phase I Study of Avelumab, Palbociclib, and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Details

This is an open-label phase I trial with a 3+3 dose escalation design. All patients will receive avelumab, cetuximab, and palbociclib. This study will enroll patients with head and neck squamous cell carcinoma not amenable to curative intent therapy. Treatment will be administered in 28 day cycles with a pre-defined dose escalation schedule.

Keywords

Head and Neck Squamous Cell Carcinoma Avelumab Palbociclib Cetuximab cancer Recurrent Head and Neck Squamous Cell Carcinoma Metastatic Head and Neck Squamous Cell Carcinoma Carcinoma Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck Avelumab, Palbociclib, and Cetuximab

Eligibility

You can join if…

Open to people ages 18 years and up

  • Histologically or cytologically proven squamous cell carcinoma of the head and neck not amenable to curative intent therapy.
  • Presence of measurable tumor lesions per RECIST criteria v1.1
  • Life expectancy greater than 12 weeks.
  • Adequate hematologic, hepatic, and renal function
  • Negative serum or urine pregnancy test for women of child bearing potential

You CAN'T join if...

  • Prior therapy with an EGFR inhibitor or PD-1 or PD-L1 inhibitor in the recurrent or metastatic setting
  • Uncontrolled central nervous system metastases (stable metastases permitted)
  • Chemotherapy 28 days prior to first administration of study treatment and/or monoclonal antibody ≤8 weeks prior to first administration of study treatment.
  • History of other malignancies,
  • Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration of >10 mg/day of prednisone or equivalent)
  • Prior organ transplantation
  • Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).

Location

  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States

Lead Scientist at UCSD

  • Kathryn A Gold, MD
    Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 58 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Kathryn Gold
ID
NCT03498378
Phase
Phase 1 Research Study
Study Type
Interventional
Participants
Expecting 24 study participants
Last Updated